BERLEX' BETASERON IS APPROVABLE FOR MULTIPLE SCLEROSIS, receiving the designation from FDA during the week of May 25. Betaseron (interferon beta) will be the first product specifically approved for treatment of MS; it is also the first biologic to be designated as "approvable" during the application review process. The PLA (92-0495) revie for Betaseron was conducted under an intercenter agreement between the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. FDA and Berlex are understood to still be working on the labeling for the interferon product. Issues that may be under discussion include conditions for self-administration of Betaseron. During the clinical trials reported with the PLA, patients self-administered the injectable subcutaneously on alternate days for two years. The approvable status for Betaseron comes two months after the drug was recommended for approval in the reduction of neurological exacerbations in patients with relapsing-remitting multiple sclerosis by FDA's Peripheral & Central Nervous System Drugs Advisory Committee ("The Pink Sheet" March 22, p. 5). The committee found Betaseron effective in decreasing vision problems and improving motor coordination or tremors in people with MS. In the single Phase III multicenter trial of the interferon product on 338 MS patients, the every-other-day dosage Betaseron 45 mil. IU produced a 34% reduction in the rate of exacerbations compared to placebo. Betaseron also increased the time to first exacerbatio by 93%. Lesion area measured by MRI increased by 19.4% in the placebo group while it decreased by 4.2% in the Betaseron- treated patients.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
